ICON plc
Accellacare in-home clinical services — all phases
Vendor page claim tied to Accellacare in-home services; does not establish general CRO phase experience, sponsor-specific delivery or outcomes.
DELIVERY MODELS & SPECIALIST SERVICES
Biotech sponsors differ on how much oversight they keep in-house. Reviewed CRO pages split across end-to-end outsourcing, FSP staffing, central laboratory anchors, decentralized/in-home visits, and mid-trial rescue.
Accellacare in-home clinical services — all phases
Vendor page claim tied to Accellacare in-home services; does not establish general CRO phase experience, sponsor-specific delivery or outcomes.
full-service, single-vendor outsourcing with wholly-owned Central Labs, Bioanalytical Lab, Imaging Core Lab, ECG Core Lab and CTMS
Vendor-stated full-service model; FSP availability not offered/stated on homepage.
Integrated clinical development with Site Alliance Network, decentralized trial (DCT) elements, regulatory strategy, clinical logistics, pharmacovigilance
Vendor service statement; protocol-level site availability requires verification.
Full-service outsourcing (FSO) and Functional Service Provider (FSP 360)
Vendor offers both full-service and FSP delivery models.
full service and FSP clinical development with FDA Diversity Action Plan support
Vendor service statement; does not specify individual trial phase exclusions.
full-service partnerships, functional service partnerships (FSP), and comprehensive laboratory services
Vendor service statement; specific indication/team availability unverified.
nonclinical development, central lab services (100+ countries), and companion diagnostics (distinct lab/enablement focus)
Current biopharma page foregrounds laboratory, nonclinical, and CDx services rather than standalone full-service CRO trial management.
Phase I-IV trial execution, RWE, and Transition Studies (mid-trial rescue)
Vendor markets mid-trial transition/rescue capability.
Full-service CRO and FSP services with integrated translational/biomarker science and Precision labs
Vendor service statement.
specialty CRO combining regulatory advisory, biostatistics/InStat, clinical operations, DCT, and clinical trial rescue
Vendor service statement.
global full-service CRO with clinical research and consulting across the development lifecycle
Homepage statement only; therapeutic areas and specific trial phases sit on linked subpages not captured here.
dual-focus specialty CRO (formerly Innovaderm) with affiliated clinical research unit for North America/global trials
Headquartered in Montreal, Canada with North America trial capabilities.
global full service and FSP oncology/CGT CRO
Vendor service statement; specific trial phases not enumerated on homepage.
Full-service Phase II-IV CRO covering site feasibility, clinical operations, data management, and biostatistics
Vendor service statement; notes APAC CRO partner network alongside US work.
Biotech and MedTech CRO covering drugs, medical devices, and diagnostics (regulatory strategy, quality systems, clinical trials, RWE)
Mixed MedTech and biotech scope; confirm pure-biotech Phase II/III drug trial depth separately.
Keep a trial’s visit model separate from the functions you are outsourcing.
ICON describes traditional, decentralized and hybrid trial models on its clinical-operations page.
These describe visit/delivery models, not evidence that all functions are included in one quoted contract. Source & date